LLY trades 2.8% below Wall Street's consensus target of $1269.94.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LLY achieves its forward estimates and maintains a stable P/E multiple of 33.7x. This scenario reflects the blended consensus of 45 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Eli Lilly and Company (LLY) has a Wall Street consensus price target of $1269.94, based on estimates from 45 covering analysts. With the stock currently trading at $1235.56, this represents a potential upside of +2.8%. The company has a market capitalization of $1.17T.
Analyst price targets range from a low of $1135.00 to a high of $1400.00, representing a 21% spread in expectations. The median target of $1270.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 33 analysts rating the stock as a Buy or Strong Buy,9 rating it Hold, and 3 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LLY trades at a trailing P/E of 53.8x and forward P/E of 33.7x. The forward PEG ratio of 1.17 indicates reasonable valuation for growth. Analysts expect EPS to grow +29.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $1640.01, with bear and bull scenarios of $1033.21 and $2160.88 respectively. Model confidence stands at 53/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NVONovo Nordisk A/S | $220.6B | $49.64 | $45.00 | -9.3% | Buy | 2.3x | 39 |
PFEPfizer Inc. | $136.9B | $24.07 | $26.75 | +11.1% | Hold | 8.1x | 39 |
MRKMerck & Co., Inc. | $318.3B | $128.86 | $133.77 | +3.8% | Buy | 25.1x | 37 |
AZNAstraZeneca PLC | $299.4B | $193.12 | $186.67 | -3.3% | Buy | 18.8x | 41 |
BMYBristol-Myers Squibb Company | $118.4B | $57.97 | $62.60 | +8.0% | Hold | 9.2x | 41 |
ABBVAbbVie Inc. | $449.9B | $254.65 | $258.00 | +1.3% | Buy | 17.9x | 41 |
JNJJohnson & Johnson | $643.3B | $267.24 | $253.42 | -5.2% | Buy | 23.1x | 40 |
NVSNovartis AG | $299.6B | $157.03 | $170.00 | +8.3% | Hold | 18.0x | 25 |
AMGNAmgen Inc. | $198.7B | $368.10 | $352.50 | -4.2% | Buy | 16.4x | 38 |
BIIBBiogen Inc. | $30.4B | $205.70 | $218.32 | +6.1% | Buy | 14.2x | 48 |
Quick answers to the most common questions about buying LLY stock.
The consensus price target for LLY is $1269.94, close to the current price of $1235.56 (2.8% implied move). Based on 45 analyst estimates, the stock appears fairly valued near current levels.
LLY has a consensus rating of "Buy" based on 45 Wall Street analysts. The rating breakdown is predominantly bullish, with 33 Buy/Strong Buy ratings. The consensus 12-month price target of $1269.94 implies 2.8% upside from current levels.
LLY trades at a forward P/E of 33.7444x, representing a moderate valuation. With analysts targeting $1269.94 (2.8% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $1400 for LLY, while the most conservative target is $1135. The consensus of $1269.94 represents the median expectation. Our quantitative valuation model projects a bull case target of $2161 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
LLY is heavily covered by Wall Street, with 45 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 33 have Buy ratings, 9 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LLY stock forecast based on 45 Wall Street analysts shows a consensus price target of $1269.94, with estimates ranging from $1135 (bear case) to $1400 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $1640, with bear/bull scenarios of $1033/$2161.
Our quantitative valuation model calculates LLY's fair value at $1640 (base case), with a bear case of $1033 and bull case of $2161. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 53/100.
LLY trades at a forward P/E ratio of 33.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 53.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
LLY appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $1269.94 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LLY analyst price targets range from $1135 to $1400, a 21% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1269.94 consensus represents the middle ground. Our model's $1033-$2161 range provides an independent fundamental perspective.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.